| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Venrock Healthcare Capital Partners II, L.P. last filed a Form 4 in July 2022, as 10% Owner at VTGN. The filings on record cover 2 companies.
At the last filing, the largest reported position was 1,544,112 shares of KALV. The KALV filings lean toward selling, a net 500,000 shares.
Venrock Healthcare Capital Partners II, L.P. has 2 Form 4 filings on record from March 2019 to July 2022, across 2 companies: 10% Owner at Vistagen Therapeutics (VTGN), 2022; 10% Owner at KalVista Pharmaceuticals (KALV), 2019.
The 2 reported transactions were 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $14.4M.
The largest open-market sale was 500,000 shares of KALV at an average $28.75 on March 18, 2019, about $14.4M.
Shares as reported in the last Form 4 for each company; the most recent is from July 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.